These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18199897)

  • 1. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.
    Lefèvre G; Pommier F; Sedek G; Allison M; Huang HL; Kiese B; Ho YY; Appel-Dingemanse S
    J Clin Pharmacol; 2008 Feb; 48(2):246-52. PubMed ID: 18199897
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application.
    Lefèvre G; Sedek G; Huang HL; Saltzman M; Rosenberg M; Kiese B; Fordham P
    J Clin Pharmacol; 2007 Apr; 47(4):471-8. PubMed ID: 17389556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.
    Frankfort SV; Ouwehand M; van Maanen MJ; Rosing H; Tulner LR; Beijnen JH
    Rapid Commun Mass Spectrom; 2006; 20(22):3330-6. PubMed ID: 17044120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
    Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
    Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine exposure provided by a transdermal patch versus capsules.
    Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
    Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic rationale for the rivastigmine patch.
    Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
    Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rivastigmine patch for dementia.
    Med Lett Drugs Ther; 2008 Mar; 50(1282):21-2. PubMed ID: 18356801
    [No Abstract]   [Full Text] [Related]  

  • 8. A study of rivastigmine liposomes for delivery into the brain through intranasal route.
    Arumugam K; Subramanian GS; Mallayasamy SR; Averineni RK; Reddy MS; Udupa N
    Acta Pharm; 2008 Sep; 58(3):287-97. PubMed ID: 19103565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.
    Hossain M; Jhee SS; Shiovitz T; McDonald C; Sedek G; Pommier F; Cutler NR
    Clin Pharmacokinet; 2002; 41(3):225-34. PubMed ID: 11929322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender differences in the pharmacokinetics of rivastigmine in rats.
    Arumugam K; Chamallamudi MR; Mallayasamy SR; Ganesan S; Shavi GV; Averineni R; Reddy R; Bhat K; Udupa N
    Arzneimittelforschung; 2009; 59(10):493-7. PubMed ID: 19998576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.
    Kurz A; Farlow M; Lefèvre G
    Int J Clin Pract; 2009 May; 63(5):799-805. PubMed ID: 19392927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic profile of loprazolam in 12 young and 12 elderly healthy volunteers.
    Dorling MC; Hindmarch I
    Drugs Exp Clin Res; 2001; 27(4):151-9. PubMed ID: 11822225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin pharmacokinetics in premenopausal and postmenopausal healthy female volunteers.
    Markantonis SL; Tsakalozou E; Paraskeva A; Staikou C; Fassoulaki A
    J Clin Pharmacol; 2008 Feb; 48(2):240-5. PubMed ID: 18071190
    [No Abstract]   [Full Text] [Related]  

  • 14. A pharmacokinetic comparison of generic tablets containing bisoprolol with the innovator formulation in healthy volunteers.
    Jovanović D; Cusić S; Rancić D; Srnić D; Perković-Vukcević N
    J Clin Pharmacol; 2006 Oct; 46(10):1217-22. PubMed ID: 16988212
    [No Abstract]   [Full Text] [Related]  

  • 15. Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.
    Hsieh YH; Yang YH; Yeh HH; Lin PC; Chen SH
    Electrophoresis; 2009 Feb; 30(4):644-53. PubMed ID: 19170055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical determination and pharmacokinetics of robenacoxib in the dog.
    Jung M; Lees P; Seewald W; King JN
    J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch.
    Lefèvre G; Büche M; Sedek G; Maton S; Enz A; Lorch U; Sagan C; Appel-Dingemanse S
    J Clin Pharmacol; 2009 Apr; 49(4):430-43. PubMed ID: 19246725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
    Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
    Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and evaluation of injectable sustained-release microspheres of rivastigmine.
    Zhu Y; Zhu Z; Cao Q; Chen D; Cui J
    J Control Release; 2011 Nov; 152 Suppl 1():e131-2. PubMed ID: 22195801
    [No Abstract]   [Full Text] [Related]  

  • 20. Absolute bioavailability, pharmacokinetics, renal and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of 14C-distigmine-bromide in healthy volunteers.
    Vree TB; Waitzinger J; Hammermaier A; Radhofer-Welte S
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):393-403. PubMed ID: 10475142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.